ORAL-B
Oral-B, a leading innovator in oral health is on a mission to change this with the launch of THE BIG RETHINK, its social ambition to ensure that everybody has an equitable oral care experience - whether that’s at home or in the dentist’s chair. The brand, who is at the beginning of this journey recognizes the need to continue learning from both dental professionals and consumers who frequently experience oral health struggles to be able to make a real impact and offer an equitable oral care experience for everyone.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006117/en/
Oral-B launches The Big Rethink initiative at exclusive launch event in Frankfurt with panel of experts on how to make oral care more inclusive and accessible. Pictured (left to right): British broadcaster, Nikki Fox, Executive Board Member of the iADH, Alison Dougall, British influencer James Hunt from Stories About Autism, iADH spokesperson, Johanna Norderyd, popular German actor, Andre Dietz, Chief Executive Officer for Healthcare, Jennifer Davis and P&G Europe Oral Care Senior Vice President, Benjamin Binot. (Photo: Business Wire)
To launch THE BIG RETHINK campaign, the brand is working together with the International Association for Disability and Oral Health (iADH) to help inform the approach. The first step of this partnership is the launch of the ‘Positive Practices’ programme, designed to train and educate dental practices on how to become more confident and inclusive when it comes to their patients. The programme will not only enable Oral-B to become more educated on the physical and mental needs of those with different types of disabilities, but it will also help them to learn how to adapt their product offering and improve the oral health outcomes of those with disabilities. THE BIG RETHINK Content Hub will also offer relevant and helpful content for people with disabilities, their caregivers and families, as well as the professional dental health community. Visit: https://www.oralb.co.uk/en-gb/big-rethink.
As Oral-B celebrates 60 years since the launch of the first electric toothbrush in 1963, the brand continues to put consumer understanding and leading-edge technology at the heart of its product development by designing inclusive products that help to bring about positive change in oral care for everyone. The brand is also developing a series of tools to support dentists within their practices, such as student training and accreditation programmes.
To celebrate the launch of THE BIG RETHINK, a brand film was unveiled last night at an exclusive launch event in Frankfurt, Germany. The event was an opportunity for Oral-B to set out its ambitions of THE BIG RETHINK and discuss the findings of The Oral Health & Disability European Study with an influential panel of speakers. Including P&G’s Chief Executive Officer for Healthcare, Jennifer Davis, iADH spokesperson, Johanna Norderyd, British broadcaster, Nikki Fox, British influencer James Hunt from Stories About Autism and popular German actor, Andre Dietz.
Jennifer Davis, P&G Chief Executive Officer, Healthcare says: “As a leading innovator in oral health for over 70 years and the world’s #1 dentist recommended toothbrush brand, we recognise the importance of making oral care accessible to all. We are indeed at the beginning of a very exciting journey, and we will continue to learn from both dental professionals and consumers to ensure we are creating positive oral care solutions for everyone – I really believe that this is the beginning of an initiative that has a global footprint.”
Benjamin Binot, P&G Europe Oral Care Senior Vice President comments: “Addressing the significant oral health inequalities experienced by people with disabilities in Europe is a huge priority for Oral-B. Our research shows that today, there are many oral health struggles amongst this audience – 1 in 5 (20%) of those with severe disabilities find brushing all their teeth physically challenging* and over a third of people with disabilities feel anxious or frustrated when it comes to visiting the dentist*. We want to help change this and believe that everyone should have an equitable oral health experience. Through our work with the iADH and the creation of the Positive Practices programme, we want to not only provide dental practices with educational materials to make their practices more inclusive, but also give the disabled community the tools they need to have more autonomy over their own oral health.
Alison Dougall, Professor in Special Care Dentistry, and an Executive Board member of iADH says; “We are delighted to have partnered with Oral-B to address the oral health struggles that are experienced by people with disabilities in Europe. Our shared values will enable us to make a huge difference to the oral care experience for people living with visible and nonvisible disabilities. We recognise that many healthcare professionals have not received education in special care dentistry during their training, and so by raising awareness around the issue and supporting those with disabilities, we can help to make small but significant adjustments to their oral health routines.”
-ENDS-
About Oral-B
Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.
About the research
– The Oral Health & Disability European Study – UK, France, Germany and Italy, was conducted by Reputation Leaders.
– The studies were conducted between 2021 – 2022 in Germany (n=1034), France (n=1009), UK (n=2029) and Italy (n=1002). In each country the online survey sample was recruited and reported to be representative of the total adult population by age, gender and region.
– The margin of error of a sample of 5000 adults is +/- 1.4% at a 95% confidence level for the 4 leading economies.
– At a country level, the margin of error of the sample relative to the total adult population was UK n=2000 (+/- 2.2%), Germany, France and Italy, n=1000 (+/- 3.1%)
+ Assumes total EU and UK population, 2022
About The iADH (International Association for Disability and Oral Health)
The iADH is a global organization with over 8000 members from all sectors of health and social care interested in disability and oral health who work to share their scientific knowledge, research, clinical skills and collective experience to reduce barriers to care and improve oral health outcomes for people with disability.
For more information, please visit: https://www.oralb.co.uk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006117/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
World FZO Concludes Its 11th World Congress in Hainan13.10.2025 12:14:00 CEST | Press release
More than 1,200 Participants from 70 Countries and 16 High-Level Ministerial Delegations The World Free Zones Organization concluded its 11th Annual World Congress in Hainan, hosted from October 10-12. The event attracted more than 1,200 participants from 70 countries, along with 16 high-level ministerial delegations and representatives of international economic and trade organisations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013845341/en/ HE Miguel Lecaro, Ambassador of the Republic of Panama to China, receiving the flag from H.E. Dr. Mohammed Al Zarooni (Photo: AETOSWire) The final day featured the Annual General Assembly meeting, during which a set of strategic resolutions aimed at enhancing the organisation’s operational framework and strengthening its global network of free zones was adopted. Elections were also held for the World FZO Board of Directors for a new term. The closing ceremony was attended by Liu
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA13.10.2025 12:00:00 CEST | Press release
Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory mantle cell lymphoma (MCL)BeOne to participate in Project Orbis program, supporting efforts to rapidly advance global access BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Additionally, the FDA has accepted BeOne’s request for participation in Project Orbis, an initiative that provides a framework for concurrent submission and review of oncology products among participating global health authorities. “Breakthrough Therapy Designation is reserved for medicines with the potential to transform outcomes for pati
Datassential Names Pascal Hartwig General Manager of EMEA, Releases First-Annual Top Chains in Europe Report13.10.2025 09:00:00 CEST | Press release
Datassential, the leading global food and beverage intelligence platform, announced the appointment of Pascal Hartwig as General Manager of EMEA. This expansion is part of Datassential's ongoing strategy to shape the future of food and beverage intelligence with a unified platform that delivers scale, speed, and precision for every customer type across the foodservice industry, including operators, manufacturers, distributors and suppliers. Hartwig’s leadership marks a pivotal step in positioning Datassential as the definitive source of truth in Europe, the Middle East, and Africa — building on its North American dominance to establish a stronger global footprint. Pascal was previously the Chief Product Officer at BeZero Carbon, and held senior leadership roles at S&P Global Market Intelligence. During his career, Pascal has established a strong track record in financial services, data solutions, product innovation and delivering value to customers. “Pascal's appointment reflects Datas
I-Pulse Welcomes Codelco as Strategic Investor13.10.2025 07:00:00 CEST | Press release
World’s Largest Copper Producer Joins Mining Majors Backing I-Pulse TechnologyI-Pulse Employs High Pulsed Power to Create Disruptive Solutions for Resource Discovery, Mining, Manufacturing, Agriculture and Geothermal Energy I-Pulse Co-Founder, Chairman and CEO Robert Friedland and Laurent Frescaline, Co-Founder and Chief Technology Officer, are pleased to welcome Codelco as the company’s latest strategic investor and key partner in the development and commercialization of its disruptive pulsed power technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251012216264/en/ I-Pulse Co-Founder Chairman and CEO Robert Friedland and Codelco Chairman Máximo Pacheco Codelco, the world’s largest copper miner, will provide capital and real-world experience to accelerate the commercialization of I-Pulse’s breakthrough innovations for drilling, continuous underground mining, tunnelling and rock crushing. Codelco joins world leading
AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 202513.10.2025 01:31:00 CEST | Press release
Results from the Phase 1b dose escalation of the TheraPb Phase 1/2 trial are the first clinical data for a Lead-212 (212Pb)-based-PSMA radioligand therapy The abstract presents a favorable safety profile for 212Pb-ADVC001 and promising anti-tumor activity, underscoring its potential to enhance therapeutic options for patients with metastatic prostate cancer The upcoming presentation at ESMO will feature updated safety and efficacy results from all seven Phase 1b treatment cohorts AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, announces a presentation at the European Society for Medical Oncology (ESMO) Congress, taking place in Berlin, Germany, from October 17-21, 2025. The presentation will feature promising results from the Phase 1b dose escalation of the Phase 1/2 TheraPb study, evaluating ADVC001, a Lead-212-based PSMA-targeted alpha therapy, in metastatic castration-resistant prostate cancer (mCRPC). This will be t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom